Clinical Trial Update: Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

View source ↗

Summary

A clinical trial is evaluating the effectiveness of a Jak1/3 inhibitor for Blau syndrome and is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blau Syndrome

Drugs mentioned

• JAK1/JAK3 inhibitor (JAK1/JAK3 inhibitor)

Snippet

Sponsor: Tongji Hospital | Conditions: Blau Syndrome | Status: ENROLLING_BY_INVITATION